Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma

Abstract

Bcl-2 or Bcl-XL confers resistance to chemotherapy in multiple myeloma (MM). Here we characterized the effects of ABT-737, a potent small-molecule inhibitor of antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w with markedly higher affinity than previously reported compounds, on human MM cells. ABT-737 induces apoptosis in MM cells, including those resistant to conventional therapy. Examination of purified patient MM cells demonstrated similar results, without significant toxicity against normal peripheral blood mononuclear cells and MM bone marrow stromal cells. Importantly, ABT-737 decreases the viability of bortezomib-, dexamethasone-(Dex) and thalidomide-refractory patient MM cells. Additionally, ABT-737 abrogates MM cell growth triggered by interleukin-6 or insulin-like growth factor-1. Mechanistic studies show that ABT-737-induced apoptosis is associated with activation of caspase-8, caspase-9 and caspase-3, followed by poly(ADP-ribose) polymerase cleavage. Combining ABT-737 with proteasome inhibitor bortezomib, melphalan or dexamethasone induces additive anti-MM activity. Taken together, our study provides the rationale for clinical protocols evaluating ABT-737, alone and together with botezomib, mephalan or dexamethasone, to enhance MM cell killing, overcome drug resistance conferred by Bcl-2 and improve patient outcome in MM.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Bossy-Wetzel E, Green DR . (1999). Apoptosis: checkpoint at the mitochondrial frontier. Mutat Res 434: 243–251.

    Article  CAS  Google Scholar 

  • Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351–365.

    Article  CAS  Google Scholar 

  • Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al. (2005a). A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8: 407–419.

    Article  CAS  Google Scholar 

  • Chauhan D, Hideshima T, Anderson KC . (2005b). Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45: 465–476.

    Article  CAS  Google Scholar 

  • Chou TC, Talalay P . (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55.

    Article  CAS  Google Scholar 

  • Cory S, Adams JM . (2005). Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8: 5–6.

    Article  CAS  Google Scholar 

  • Dalton WS . (2002). Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: NJ Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res. 8: 3658–3668. Clin Cancer Res 8: 3643–3645.

    Google Scholar 

  • Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T et al. (2001). Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3: 173–182.

    Article  CAS  Google Scholar 

  • Fulda S, Meyer E, Debatin KM . (2002). Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283–2294.

    Article  CAS  Google Scholar 

  • Gazitt Y, Fey V, Thomas C, Alvarez R . (1998). Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 13: 397–405.

    CAS  PubMed  Google Scholar 

  • Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H et al. (1994). Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84: 3063–3070.

    CAS  PubMed  Google Scholar 

  • Jelinek DF, Witzig TE, Arendt BK . (1997). A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 159: 487–496.

    CAS  PubMed  Google Scholar 

  • Kluck RM, Kashibatta S . (1997). A lively meeting of a deathly topic. Apoptosis 2: 337–342.

    Article  CAS  Google Scholar 

  • Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Itshitsuka K et al. (2004). VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis. Blood 104: 2886–2892.

    Article  CAS  Google Scholar 

  • Liston P, Fong WG, Korneluk RG . (2003). The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22: 8568–8580.

    Article  CAS  Google Scholar 

  • Liu Q, Gazitt Y . (2003). Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 101: 4105–4114.

    Article  CAS  Google Scholar 

  • Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. (2003). Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101: 4055–4062.

    Article  CAS  Google Scholar 

  • Oberhammer FA, Hochegger K, Froschl G, Tiefenbacher R, Pavelka M . (1994). Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activation of cdc2 kinase. J Cell Biol 126: 827–837.

    Article  CAS  Google Scholar 

  • Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.

    Article  CAS  Google Scholar 

  • Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . (2006). The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107: 257–264.

    Article  CAS  Google Scholar 

  • Petros AM, Olejniczak ET, Fesik SW . (2004). Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644: 83–94.

    Article  CAS  Google Scholar 

  • Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al. (2005). Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282–6293.

    Article  CAS  Google Scholar 

  • van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM . (2003). Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 17: 211–219.

    Article  CAS  Google Scholar 

  • Willie AH, Kerr JF, Currie AR . (1980). Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–306.

    Article  Google Scholar 

  • Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. (2005). Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19: 1248–1252.

    Article  CAS  Google Scholar 

  • Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A . (1997). Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 97: 429–440.

    Article  CAS  Google Scholar 

  • Yang J, Liu X, Balla K, Kim CN, Ibardo NM, Cai J et al. (1997). Prevention of apoptosis by Bcl-2-release of cytochrome-c from the mitochondria blocked. Science 275: 1129–1136.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This investigation was supported by NIH grants RO-1 CA 50947, PO-1 CA 78373 and IP50CA10070, a Doris Duke Distinguished Clinical Research Scientist Award (KCA), The Myeloma Research Fund, and The Cure Myeloma Fund.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K C Anderson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chauhan, D., Velankar, M., Brahmandam, M. et al. A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26, 2374–2380 (2007). https://doi.org/10.1038/sj.onc.1210028

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210028

Keywords

This article is cited by

Search

Quick links